{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:08:16Z","timestamp":1793725696811,"version":"4.6.1"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To integrate pharmacovigilance and network pharmacology methods for a comprehensive analysis of the potential adverse reactions of complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan) and neonatal Fc receptor (FcRn) inhibitors (efgartigimod, rozanolixizumab), and to explore their toxicity mechanisms, thereby providing a reference for rapidly understanding the safety of these two novel classes of biologics in the treatment of myasthenia gravis (MG).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We extracted adverse event (AE) reports for these five drugs from the FDA Adverse Event Reporting System (FAERS) database, limited to the period since their FDA approval for the treatment of MG. Reports were further restricted to those where the drug was listed as the primary suspect (PS) and the indication (INDI) was \u201cMG\u201d. Signal detection was performed using the Reporting Odds Ratio (ROR) method, the UK Medicines and Healthcare products Regulatory Agency (MHRA) method, and the Bayesian Confidence Propagation Neural Network (BCPNN) method. Additionally, network pharmacology was employed to analyze the toxicity mechanisms of the system organ categories (SOCs) specifically associated with complement C5 inhibitors and FcRn inhibitors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Signal detection of AE reports associated with these five drugs revealed previously unlabeled positive signals, including: eculizumab (gastric cancer, embolic stroke), ravulizumab (psoriatic arthropathy, hypoacusis, peripheral vascular disorders), zilucoplan (weight increased, weight decreased), efgartigimod (metastases to liver, hepatic failure, nephrolithiasis, dysuria, Prostatitis, prostate cancer, Angina pectoris, congestive cardiac failure) and rozanolixizumab (vomiting, dyspepsia). However, the gastric cancer, liver metastasis and prostate cancer were reported within the first 30 days, causal associations cannot be established based on the data presented. Potential toxicity analysis was conducted on noteworthy SOCs for complement C5 inhibitors and FcRn inhibitors, revealing key targets and pathways.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study elucidated the safety profiles of complement C5 inhibitors and FcRn inhibitors in clinical practice through pharmacovigilance analysis, confirming known adverse reactions and identifying several previously unreported ones. Furthermore, network pharmacology analysis revealed potential mechanisms underlying these adverse reactions. These findings provide valuable insights for monitoring and managing risks during treatment with two novel classes of biologics.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1667249","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T04:18:35Z","timestamp":1759897115000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety profile of complement C5 inhibitors and FcRn inhibitors in the treatment of myasthenia gravis: analysis of the FAERS database and disease-gene interaction network"],"prefix":"10.3389","volume":"16","author":[{"given":"Luqiong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc","year":"2021","journal-title":"J Med Life"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","article-title":"The course of myasthenia gravis and therapies affecting outcome","volume":"505","author":"Grob","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e001076","DOI":"10.1136\/bmjno-2025-001076","article-title":"Epidemiology and patient characteristics of the US myasthenia gravis population: real-world evidence from a large insurance claims database","volume":"7","author":"Miller-Wilson","year":"2025","journal-title":"BMJ Neurol Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-095496","article-title":"Impact of 2014 Japanese practice guidelines on treatment patterns in patients with myasthenia gravis: an insurance claims database study","volume":"15","author":"Konno","year":"2025","journal-title":"BMJ Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2025.101970","article-title":"A comprehensive review of the treatment options in myasthenia gravis","volume":"20","author":"Randall","year":"2025","journal-title":"Dis Mon"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27220","article-title":"Thymoma pathology and myasthenia gravis outcomes","volume":"63","author":"Menon","year":"2021","journal-title":"Muscle Nerve"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2025.06.012","article-title":"Effect of intravenous immunoglobulin or plasmapheresis in myasthenic crisis and worsening myasthenia gravis compared with or without rescue treatment","author":"Kalita","year":"2025","journal-title":"Clin Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s00415-025-13113-0","article-title":"Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis","volume":"272","author":"Hewamadduma","year":"2025","journal-title":"J Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD016208","article-title":"Immunomodulators and immunosuppressants for myasthenia gravis: a network meta-analysis","volume":"6","author":"Varela","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13019-025-03480-0","article-title":"Delving into immune modulation: thymectomy in myasthenia gravis","volume":"20","author":"Lin","year":"2025","journal-title":"J Cardiothorac Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12569-w","article-title":"United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use","volume":"271","author":"Habib","year":"2024","journal-title":"J Neurol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-03014-5","article-title":"Risk-benefit analysis of novel treatments for patients with generalized myasthenia gravis","volume":"41","author":"Smith","year":"2024","journal-title":"Adv Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-024-00649-3","article-title":"Targeted treatments for myasthenia gravis in children and adolescents","volume":"26","author":"Ramdas","year":"2024","journal-title":"Paediatr Drugs"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cells14100739","article-title":"The role of complement in the pathogenesis and treatment of myasthenia gravis","volume":"14","author":"Martinez Salazar","year":"2025","journal-title":"Cells"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e70158","DOI":"10.1111\/ene.70158","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: final results from the phase 3 CHAMPION MG open-label extension","volume":"32","author":"Vu","year":"2025","journal-title":"Eur J Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2025.108877","article-title":"Subcutaneous zilucoplan: Evaluation of reproductive toxicology","volume":"134","author":"Lemper","year":"2025","journal-title":"Reprod Toxicol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1579859","article-title":"Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2025.108910","article-title":"Efficacy and safety of FcRn inhibitors in patients with Myasthenia gravis: An updated systematic review and meta-analysis","volume":"254","author":"Akhtar","year":"2025","journal-title":"Clin Neurol Neurosurg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/1750743X.2025.2491295","article-title":"Rozanolixizumab for Myasthenia Gravis: a breakthrough treatment and future prospects","volume":"17","author":"Matic","year":"2025","journal-title":"Immunotherapy"},{"key":"B20","doi-asserted-by":"crossref","DOI":"10.1201\/9781032629940","volume-title":"Signal Analysis in Pharmacovigilance Principles and Processes","author":"Kumar","year":"2024"},{"key":"B21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","article-title":"Using MedDRA: implications for risk management","volume":"27","author":"Brown","year":"2004","journal-title":"Drug Saf"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1515730","article-title":"The real-world safety of Ofatumumab: a pharmacovigilance analysis based on the FDA adverse event reporting system","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/20523211.2025.2525356","article-title":"Age-stratified pharmacovigilance of azithromycin: a multimethod signal detection analysis in the FAERS database","volume":"18","author":"Zhang","year":"2025","journal-title":"J Pharm Policy Pract"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1586361","article-title":"Adverse drug reactions related to methotrexate: a real-world pharmacovigilance study using the FAERS database from 2004 to 2024","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1596842","article-title":"Post-marketing safety concerns with Tislelizumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2025.114671","article-title":"Comprehensive network pharmacology and experimental study to investigate the effects and mechanisms of Lophatherum gracile Brongn. for glioma treatment","volume":"10","author":"Liu","year":"2025","journal-title":"Exp Cell Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26136303","article-title":"Network pharmacology, molecular dynamics simulation, and biological validation insights into the potential of ligustri lucidi fructus for diabetic nephropathy","volume":"26","author":"Liu","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1039\/d5ra02505b","article-title":"Exploring the potential molecular targets and therapeutic mechanisms of Cyperi Rhizoma in treating diabetic cardiomyopathy: a computational approach","volume":"15","author":"Lu","year":"2025","journal-title":"RSC Adv"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28450","article-title":"MGBase: A global, observational registry for collaborative research in myasthenia gravis","volume":"72","author":"Buzzard","year":"2025","journal-title":"Muscle Nerve"},{"key":"B30","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1634\/theoncologist","article-title":"FDA report: eculizumab (Soliris) for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"13","author":"Dmytrijuk","year":"2008","journal-title":"Oncologist"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"Lancet Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1223322","article-title":"Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00210-1","article-title":"Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial","volume":"9","author":"de Latour","year":"2022","journal-title":"Lancet Haematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03630-x","article-title":"Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan","volume":"118","author":"Nishimura","year":"2023","journal-title":"Int J Hematol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1510992","article-title":"A real-world pharmacovigilance study of efgartigimod alfa in the FDA adverse event reporting system database","volume":"16","author":"Yang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-095652","article-title":"Postmarketing adverse events of efgartigimod alfa: a real-world pharmacovigilance study based on the FAERS database","volume":"15","author":"Ju","year":"2025","journal-title":"BMJ Open"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19858","article-title":"Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double-blind, placebo-controlled phase 3 studies and their open-label extension","volume":"206","author":"Cooper","year":"2025","journal-title":"Br J Haematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-334404","article-title":"C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis","volume":"96","author":"Huntemann","year":"2025","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103476","article-title":"Calprotectin and neurofilament serum levels correlate with treatment response in myasthenia gravis under intensified therapy-A pilot study","volume":"157","author":"Stascheit","year":"2025","journal-title":"J Autoimmun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol Clin"},{"key":"B42","doi-asserted-by":"publisher","first-page":"28394","DOI":"10.1038\/s41598-024-79918-7","article-title":"Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis","volume":"14","author":"Ma","year":"2024","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/22143602241308181","article-title":"Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension","volume":"12","author":"Habib","year":"2025","journal-title":"J Neuromuscul Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1565480","article-title":"Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024","volume":"16","author":"Xia","year":"2025","journal-title":"Front Pharmacol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1409480","article-title":"Efgartigimod-associated Kaposi\u2019s varicelliform eruption and herpetic conjunctivitis in a patient with seropositive ocular myasthenia gravis: a case report and review","volume":"15","author":"Ge","year":"2024","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/cvr\/cvad017","article-title":"Fibrin clot properties in cardiovascular disease: from basic mechanisms to clinical practice","volume":"119","author":"Z\u0105bczyk","year":"2023","journal-title":"Cardiovasc Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2025.109158","article-title":"Atypical complications and co-morbidities of type 1 diabetes in young adults","volume":"39","author":"James","year":"2025","journal-title":"J Diabetes Complications"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008837","article-title":"RNA sequencing uncovers the key microRNAs potentially contributing to sudden sensorineural hearing loss","volume":"96","author":"Li","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/biom15081086","article-title":"A Natural Polyphenol, Chlorogenic Acid, Attenuates Obesity-Related Metabolic Disorders in Male Rats via miR-146a-IRAK1-TRAF6 and NRF2-Mediated Antioxidant Pathways","volume":"15","author":"Alenezi","year":"2025","journal-title":"Biomolecules"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5584681","article-title":"Biodata mining of differentially expressed genes between acute myocardial infarction and unstable angina based on integrated bioinformatics","volume":"2021","author":"Guo","year":"2021","journal-title":"BioMed Res Int"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1667249\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T04:18:36Z","timestamp":1759897116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1667249\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":50,"alternative-id":["10.3389\/fimmu.2025.1667249"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1667249","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"article-number":"1667249"}}